Treatment of uraemic bleeding with conjugated oestrogen.
A conjugated oestrogen preparation ('Premarin') was given to 6 uraemic patients with abnormal bleeding tendency in whom bleeding time was more than 30 min despite their being on chronic dialysis. In 4 patients the bleeding time became normal after 2 to 5 days of premarin therapy. In 1 of the 4 the prolonged bleeding time was repeatedly restored to normal (less than 7 min) after a single dose of premarin (25 mg). Bleeding time remained normal for 3 to 10 days after discontinuation of premarin. Bleeding time was significantly shortened (11 min) in the other 2 patients after 7 and 9 days of treatment. There was no consistent improvement in platelet aggregation nor increase in plasma factor-VIII-ristocetin cofactor activity during premarin therapy. 5 patients underwent surgery without abnormal bleeding. There were no side effects associated with premarin administration. Premarin treatment may be beneficial to uraemic patients with abnormal bleeding.
D000328:Adult; D001760:Bleeding Time; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use*; D005169:Factor VIII / Q000032:analysis; D005260:Female; D006470:Hemorrhage / Q000209:etiology / Q000517:prevention & control*; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D011183:Postoperative Complications; D006435:Renal Dialysis; D014511:Uremia / Q000097:blood* / Q000150:complications / Q000188:drug therapy
D004966:Estrogens, Conjugated (USP); D005169:Factor VIII